Hepion Pharmaceuticals, Inc. (HEPA) Form SCHEDULE 13D — Aug 20, 2026
Gary Stetz, a director and interim CEO of Hepion Pharmaceuticals, filed a Schedule 13D disclosing beneficial ownership of 5,250,000 shares of common stock, equal to 5.7% of the class, with full sole voting and dispositive power. Stetz built the stake through two Securities Purchase Agreements: 1,250,000 shares for $50,000 on April 21, 2026, and 2,000,000 shares plus a warrant for another 2,000,000 shares (exercisable at $0.06) for $100,000 on July 31, 2026, for an aggregate of roughly $150,000. He states the purchases were for investment purposes with no plans or proposals to influence the company, though he may acquire additional shares from time to time.
Key figures
- Date Of Event
- 2026-08-03
- Warrant Shares
- 2000000
- Percent Of Class
- 5.7%
- Warrant Exercise Price
- 0.06
- July2026 Purchase Price
- $100,000
- Aggregate Purchase Price
- $150,000
- April2026 Purchase Price
- $50,000
- July2026 Purchase Shares
- 2000000
- April2026 Purchase Shares
- 1250000
- Beneficial Ownership Shares
- 5250000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.